Ten Washington state health organizations recently received grants of up to $15,000 from Fred Hutch Cancer Center’s Community ...

At first glance, art and science might seem like opposite worlds — one driven by imagination and emotion, the other by data ...

In 2024, Obliteride raised more than $9 million for research at Fred Hutch, contributing to more than $58 million raised since 2013. These funds have fueled urgently needed advances in cancer ...

Dr. Folashade Otegbeye, facility director of the Therapeutic Products Program at Fred Hutch, works to rapidly translate what ...

A study from Fred Hutch Cancer Center finds that some cancer patients' antibodies can boost their response to immunotherapy treatment.

A Fred Hutch Cancer Center outpatient complex serving more than 60,000 adult patients per year will be renamed the Sloan Clinic in recognition of Stuart and Molly Sloan, who have increased their total ...

Patient provider profile for Dr. Michael Schweizer, medical oncologist at Fred Hutchinson Cancer Center.

A small observational study out of the U.K. of breast cancer patients found that certain types of chemotherapy can weaken part of the immune system for up to nine months after treatment.

There's a growing interest in the use of bone-modifying agents, or BMAs, known as bisphosphonates in the cancer patient population. But these agents can cause short- and long-term side effects. What’s ...

Far too many cancer patients face barriers to participating in clinical trials due to overly restrictive trial criteria. Here's how Fred Hutch researchers are changing that..